The Federal Circuit's affirmance permanently eliminates the $107.5M jury verdict and the patent infringement overhang on Tagrisso from these Wyeth patents. Tagrisso is a key AstraZeneca oncology product; this ruling removes a material IP risk. Monitor for any Wyeth petition for certiorari (unlikely given the fact-specific enablement holding) and for any remaining patent challenges on Tagrisso from other parties.
Price Chart
Executive Summary
The Federal Circuit affirmed the district court's grant of JMOL of invalidity for lack of enablement of Wyeth's asserted patents (U.S. Patent 10,603,314 and 10,596,162) covering methods of treating gefitinib/erlotinib-resistant NSCLC with irreversible EGFR inhibitors. The ruling permanently removes the patent infringement risk to AstraZeneca's Tagrisso (osimertinib) and vacates the $107.5M jury verdict against AstraZeneca, eliminating a material liability and IP overhang.
Court Ruling Details
Key Facts
- Federal Circuit affirmed district court's JMOL of invalidity for lack of enablement of Wyeth's asserted claims in U.S. Patents 10,603,314 and 10,596,162
- The ruling vacates the $107,500,000 jury verdict against AstraZeneca for induced infringement of Tagrisso (osimertinib)
- The patents claimed methods of treating gefitinib/erlotinib-resistant NSCLC with irreversible EGFR inhibitors; the court found the specification failed to enable a daily unit dosage for human patients without undue experimentation
- The Federal Circuit affirmed that the specification provided no working examples of unit dosages in patients and disclosed dosage ranges that were toxic for at least two of the three preferred compounds
- This is a final appellate ruling from the Federal Circuit, the authoritative court for patent appeals, and is not subject to further appeal as of right
Financial Impact
Vacates $107,500,000 jury verdict against AstraZeneca and permanently removes patent infringement risk on Tagrisso (osimertinib) from these Wyeth patents
Risk Factors
- Wyeth could petition for certiorari to the Supreme Court, though the fact-specific enablement holding makes this unlikely
- Other patent challenges to Tagrisso from different patent holders remain possible
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-f42fbd41d9-AZN |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $161.85 $168.37 | ▲ +4.03% | ▲ +1.90% | $156.97 (−3.02%) |
Sep 14, 2026 18d ago | 6-K | $163.78 $168.10 | ▼ −2.64% | ▼ −2.53% | $156.97 (+4.16%) |
Sep 8, 2026 24d ago | 6-K | $160.04 $161.85 | ▲ +1.13% | ▲ +2.25% | $156.97 (−1.92%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.97 (−3.23%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.97 (−3.23%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $156.97 (−3.39%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.97 (−3.23%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.97 (−3.23%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $156.97 (−3.39%) |
Aug 31, 2026 4w ago | Court Ruling | $162.13 $159.95 | ▲ +1.34% | ▲ +1.20% | $156.97 (+3.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access